- Home
- GROV vs TARA Comparison
GROV vs TARA Comparison
Compare GROV & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROV
- TARA
- Stock Information
- Founded
- GROV 2016
- TARA N/A
- Country
- GROV United States
- TARA United States
- Employees
- GROV N/A
- TARA N/A
- Industry
- GROV Package Goods/Cosmetics
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GROV Consumer Discretionary
- TARA Health Care
- Exchange
- GROV Nasdaq
- TARA Nasdaq
- Market Cap
- GROV 55.3M
- TARA 39.6M
- IPO Year
- GROV N/A
- TARA N/A
- Fundamental
- Price
- GROV $1.30
- TARA $2.32
- Analyst Decision
- GROV Buy
- TARA Strong Buy
- Analyst Count
- GROV 1
- TARA 2
- Target Price
- GROV $2.00
- TARA $24.00
- AVG Volume (30 Days)
- GROV 76.7K
- TARA 193.0K
- Earning Date
- GROV 11-07-2024
- TARA 11-05-2024
- Dividend Yield
- GROV N/A
- TARA N/A
- EPS Growth
- GROV N/A
- TARA N/A
- EPS
- GROV N/A
- TARA N/A
- Revenue
- GROV $227,251,000.00
- TARA N/A
- Revenue This Year
- GROV N/A
- TARA N/A
- Revenue Next Year
- GROV $5.97
- TARA N/A
- P/E Ratio
- GROV N/A
- TARA N/A
- Revenue Growth
- GROV N/A
- TARA N/A
- 52 Week Low
- GROV $1.19
- TARA $1.04
- 52 Week High
- GROV $2.49
- TARA $5.24
- Technical
- Relative Strength Index (RSI)
- GROV 45.20
- TARA 63.45
- Support Level
- GROV $1.26
- TARA $2.21
- Resistance Level
- GROV $1.39
- TARA $2.42
- Average True Range (ATR)
- GROV 0.08
- TARA 0.18
- MACD
- GROV -0.01
- TARA 0.06
- Stochastic Oscillator
- GROV 12.12
- TARA 78.75
About GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).